Blue Medical Devices Announces the CE Marking of Drug Eluting Balloon Protégé NC
News Nov 01, 2012
The new device will be launched worldwide. It follows the introduction of Blue Medical’s CE marked Drug Eluting Balloon Protégé and CoCr Stent on Drug Eluting Balloon Pioneer in March of this year. Blue Medical will continue to develop their novel DEB technologies into additional applications both for coronary and peripheral application.
Non compliant PTCA balloons are commonly used to post-dilatate stents and to treat in stent restenosis (ISR). With the introduction of Drug Eluting Balloons medication was added to PTCA balloon treatment. But the need for precise and powerful dilatation remained. “Combining a drug eluting balloon with the characteristics of the proven treatment advantages of a non compliant balloon is a logical next step” said Ronald Horvers, Blue Medical’s CTO and CFO. “With Protégé NC we succeeded in combining safe and reproducible drug delivery with precise and powerful dilatation in one device. Thus reducing on the one hand procedural costs and post procedural medication requirements and at the same time increasing procedure efficiency, safety and patients comfort. In addition to these advantages the performance, profile and flexibility of a normal workhorse PTCA balloon are maintained, making the device easy to work with.”
“This new non compliant DEB completes the coronary drug eluting product line of Blue Medical”, said Noel Coopmans, CEO. “It’s another landmark in the company’s history of developing unique and innovative products. I trust it will contribute to the further growth of Blue Medical in the years ahead”.
Fermentation Byproduct Suppresses Seizures in Nerve Agent PoisoningNews
A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018